0000950103-16-014078.txt : 20160610 0000950103-16-014078.hdr.sgml : 20160610 20160610121051 ACCESSION NUMBER: 0000950103-16-014078 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 3 CONFORMED PERIOD OF REPORT: 20160610 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20160610 DATE AS OF CHANGE: 20160610 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Shire plc CENTRAL INDEX KEY: 0000936402 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-29630 FILM NUMBER: 161707948 BUSINESS ADDRESS: STREET 1: HAMPSHIRE INTL BUSINESS PARK STREET 2: CHINEHAM BASINGSTOKE CITY: HAMPSHIRE ENGLAND RG STATE: X0 ZIP: RG24 8EP BUSINESS PHONE: 441256894000 MAIL ADDRESS: STREET 1: HAMPSHIRE INTL BUSINESS PARK STREET 2: CHINEHAM BASINGSTOKE CITY: HAMPSHIRE ENGLAND RG STATE: X0 ZIP: RG24 8EP FORMER COMPANY: FORMER CONFORMED NAME: Shire Ltd. DATE OF NAME CHANGE: 20080523 FORMER COMPANY: FORMER CONFORMED NAME: Shire plc DATE OF NAME CHANGE: 20051125 FORMER COMPANY: FORMER CONFORMED NAME: SHIRE PHARMACEUTICALS GROUP PLC DATE OF NAME CHANGE: 19980302 8-K 1 dp66455_8k.htm FORM 8-K

 


 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): June 10, 2016

 

SHIRE PLC

(Exact name of registrant as specified in its charter)

 

Jersey, Channel Islands 0-29630 98-0601486
(State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.)

 

5 Riverwalk, Citywest Business Campus, Dublin 

24, Republic of Ireland
(Address of principal executive offices)

 

 Registrant’s telephone number, including area code:     +353 1 429 7700

 

(Former name or former address, if changed since last report)

  

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2.):

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

Item 8.01.Other Events

 

Shire plc has issued the press release attached hereto as Exhibit 99.1 which is incorporated by reference herein.

 

Item 9.01.Financial Statements and Exhibits

 

(d) Exhibits.  The following exhibit is furnished herewith:

 

99.1Press Release dated June 10, 2016

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  Shire plc
       
  By: /s/ W R Mordan
    Name: Bill Mordan
    Title: Company Secretary

 

Date: June 10, 2016

 

 

EXHIBIT INDEX

 

Exhibit No. 

 

Description

99.1   Press Release dated June 10, 2016

 

  

EX-99.1 2 dp66455_ex9901.htm EXHIBIT 99.1

 

Exhibit 99.1

 

Press Release

www.shire.com

 

 

 

 

Holding(s) in Company

 

June 10, 2016 - Shire plc (LSE: SHP, NASDAQ: SHPG)

 

1. Identity of the issuer or the underlying issuer
of existing shares to which voting rights are
attached: ii
Shire plc
2 Reason for the notification (please tick the appropriate box or boxes):
An acquisition or disposal of voting rights  
An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached  
An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments  
An event changing the breakdown of voting rights X
Other (please specify):  

3. Full name of person(s) subject to the
notification obligation: iii
Deutsche Bank AG
4. Full name of shareholder(s)
 (if different from 3.):iv

Deutsche Bank AG, London Branch

 

5. Date of the transaction and date on
which the threshold is crossed or
reached: v
07/06/2016
6. Date on which issuer notified: 09/06/2016
7. Threshold(s) that is/are crossed or
reached: vi, vii
Below notifiable threshold
 
 
8. Notified details:
A: Voting rights attached to shares viii, ix

Class/type of
shares

 


if possible using
the ISIN CODE

 

Situation previous
to the triggering
transaction
Resulting situation after the triggering transaction
Number
of
Shares
Number
of
Voting
Rights
Number
of shares
Number of voting
rights
% of  voting rights x
Direct Direct xi Indirect xii Direct Indirect
JE00B2QKY057 28,378,378 28,378,378

Below

notifiable

threshold

Below

notifiable

threshold

0

Below

notifiable

threshold

0

 

B: Qualifying Financial Instruments
Resulting situation after the triggering transaction
Type of financial
instrument
Expiration
date xiii
Exercise/
Conversion Period xiv
Number of voting
rights that may be
acquired if the
instrument is
exercised/ converted.
% of voting
rights
   



  

 

C: Financial Instruments with similar economic effect to Qualifying Financial Instruments xv, xvi
Resulting situation after the triggering transaction
Type of financial
instrument
Exercise price Expiration date xvii Exercise/
Conversion period xviii

Number of voting rights instrument refers to

 

% of voting rights xix, xx

 

          Nominal Delta
   

 

Total (A+B+C)
Number of voting rights Percentage of voting rights
Below notifiable threshold Below notifiable threshold
 
 
9. Chain of controlled undertakings through which the voting rights and/or the
financial instruments are effectively held, if applicable: xxi

 

 

 

 

 

 

 

 

 

 

 
Proxy Voting:
10. Name of the proxy holder:  
11. Number of voting rights proxy holder will cease
to hold:
 
12. Date on which proxy holder will cease to hold
voting rights:
 

 


13. Additional information:



 

14. Contact name: Stacy Otieno
15. Contact telephone number: 02075476268

 

 

For further information please contact:

 

Investor Relations    
     
Sarah Elton-Farr seltonfarr@shire.com +44 1256 894157
 
 

NOTES TO EDITORS

 

Shire enables people with life-altering conditions to lead better lives.

 

Shire is the leading global biotechnology company focused on serving people with rare diseases and other highly specialized conditions. We have best-in-class products available in more than 100 countries across core therapeutic areas including Hematology, Immunology, Neuroscience, Lysosomal Storage Disorders, Gastrointestinal / Internal Medicine / Endocrine and Hereditary Angioedema; a growing franchise in Oncology; and an emerging, innovative pipeline in Ophthalmics.

 

Our employees come to work every day with a shared mission: to develop and deliver breakthrough therapies for the hundreds of millions of people in the world affected by rare diseases and other high-need conditions, and who lack effective therapies to live their lives to the fullest.

 

www.shire.com

 

 

 

 

GRAPHIC 3 image_002.jpg GRAPHIC begin 644 image_002.jpg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end